sorafenib has been researched along with gsk2656157 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (gsk2656157) | Trials (gsk2656157) | Recent Studies (post-2010) (gsk2656157) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 29 | 0 | 29 |
| Protein | Taxonomy | sorafenib (IC50) | gsk2656157 (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.245 | |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | 0.905 | |
| Receptor-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 0.0691 | |
| Eukaryotic translation initiation factor 2-alpha kinase 1 | Homo sapiens (human) | 0.46 | |
| Eukaryotic translation initiation factor 2-alpha kinase 3 | Homo sapiens (human) | 0.0154 | |
| eIF-2-alpha kinase GCN2 | Homo sapiens (human) | 3.388 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E | 1 |
1 review(s) available for sorafenib and gsk2656157
| Article | Year |
|---|---|
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases | 2022 |